SCHEMBL4789485

SCHEMBL4789485

CC(C)C(=O)Oc1ccc(C(=O)N(C)c2nc(-c3ccncc3)n[nH]2)c(O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 2/20 0.36
PDK2 Q15119 2/20 0.36
PDK1 Q15118 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
ELANE P08246 2/20 0.36
GRM1 Q13255 1/20 0.35
PDE10A Q9Y233 1/20 0.35
CA2 P00918 1/20 0.33
THRB P10828 1/20 0.33
HPGDS O60760 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
KDM4E B2RXH2 3/20 0.33
ROCK2 O75116 3/20 0.33
GRK2 P25098 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPK8 P45983 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811243 0.91 KDM4E (0.39) HSP90AA1PDK2PDK1PDK3PDK4
SCHEMBL4790650 0.86 PDK2 (0.39) HSP90AA1PDK2PDK1PDK3PDK4
SCHEMBL4789487 0.77 GRK2 (0.49) ROCK2GRK2PRKCA
SCHEMBL4788081 0.77 ELANE (0.47) ELANEGRM1PDE10ACA2HPGDS
SCHEMBL4790262 0.72 ELANE (0.46) ELANEGRM1HPGDSKDM4EROCK2
SCHEMBL4788586 0.70 GRM1 (0.43) GRM1HPGDSKDM4EROCK2GRK2
SCHEMBL4790122 0.70 GRM1 (0.47) GRM1HPGDSKDM4EROCK2GRK2
SCHEMBL4788260 0.69 HPGDS (0.55) GRM1HPGDSKDM4EROCK2GRK2
SCHEMBL4811264 0.68 GRK2 (0.51) ROCK2GRK2PRKCA
SCHEMBL5109256 0.68 ROCK2 (0.52) PDK2PDK1PDK3PDK4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008011557-A2 HETEROARYL INHIBITORS OF RHO KINASE BORCHARDT ALLEN J (US) 2008-01-24 WO disclosed
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE Borchardt, Allen (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021217-A1 HETEROCYCLIC INHIBITORS OF RHO KINASE ROCK1, ROCK2, RHOA HSP90AA1 849/4885PDK2 1263/4885PDK1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.